A recent clinical trial has demonstrated that the drug, IONIS-HTTRx, is safe for use in people with Huntington’s disease.
Browsing: Huntington’s disease
Researchers have revealed that reducing mutant huntingtin protein in the brain could restore cognitive and psychiatric impairments in mice.
A simple blood test could detect the earliest changes caused by Huntington’s disease, even before scans pick up any signs in the brain.
Lausanne University Hospital (Switzerland) researchers reveal the promise of genome editing for the treatment of Huntington’s disease.
Ionis Pharmaceuticals recently announced their results from the IONIS-HTT Rx (RG6042) Phase I/II trial, reporting it to be the first drug in development to reduce disease-causing mutant huntingtin protein in people with Huntington’s disease.
New research suggests Huntington’s disease may provide protection from cancer.
Alzheimer’s Society give us a round-up of their dementia research highlights from 2017.
As we begin a new year on Neuro Central, we’re taking this opportunity to look back at some of the highlights across neuroscience and neurology in 2017.
A new study has suggested that monitoring levels of disease-specific microRNAs may be utilized as a potential biomarker for Huntington’s disease, potentially allowing early diagnosis.